ChemoCentryx (Mountain View, CA, USA) has also developed a small-molecule targeting CCR2 (CCX-872) evaluated in phase 1 in patients with unresectable PDAC (NCT02345408), with the objective to reduce the suppressive myeloid cells in the tumor and slow the progression of disease in these patients rather than altering the Treg recruitment in the TME [356]. Here, CCR2 is linked to neoplasm.